Integrative Cancer Therapies最新文献

{"title":"Caregiver's Kitchen: A Mixed Methods Feasibility Study of a Culinary Medicine and Coaching Intervention for Caregivers of Children With Cancer.","authors":"Brandy-Joe Milliron, Khulood Salman, Haley Schlechter, Paige Mountain, Gabrielle Longo, Jonathan M Deutsch, Tracey Jubelirer","doi":"10.1177/15347354261476641","DOIUrl":"10.1177/15347354261476641","url":null,"abstract":"<p><p>Caregivers play a central role in managing the nutrition challenges that arise during pediatric cancer treatment, yet many report insufficient knowledge, low confidence, and limited support for preparing foods that address treatment-related side effects. Culinary medicine, integrating nutrition education with hands-on cooking, may help caregivers navigate these challenges, but caregiver-centered programs in pediatric oncology are scarce. <i>Caregiver's Kitchen</i> is an eight-week, remotely delivered culinary medicine and coaching intervention designed to strengthen caregiver nutrition knowledge, cooking skills, and confidence in managing their child's symptoms. This mixed-methods feasibility study evaluated program feasibility and acceptability and explored caregiver experiences to inform refinement of a future trial. Ten caregiver-child dyads were enrolled. Caregivers participated in four live virtual culinary workshops and four individualized telephone coaching sessions. Feasibility outcomes included recruitment, retention, assessment completion, engagement, and acceptability, assessed against predefined progression criteria. Qualitative feedback was collected through post-intervention open-ended survey questions and analyzed using rapid content analysis. Three of five feasibility criteria were met. Recruitment targets were achieved (2-3 dyads/week), and engagement was high, with 80% attending ≥3 workshops and 90% completing ≥2 coaching calls. Acceptability was strong (mean ratings 4.35/5). Assessment completion declined at later time points. Qualitative findings highlighted the usefulness of practical culinary guidance, accessible recipes, and individualized coaching, while identifying scheduling constraints and lengthy assessments as barriers. Caregiver insights informed refinements to enhance feasibility, including transitioning to self-paced modules and streamlining assessments. Findings support progression to a larger pilot trial.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261476641"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13438338/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148669500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-Cancer and Immunomodulatory Activities of <i>Prangos ferulacea</i> (L.) Lindl. (APIACEAE) Extracts: An In Vitro and In Vivo Study.","authors":"Shefaa M Alzoubi, Moudi M Alasmari, Saman A Ahmad, Heba K Alshaeri, Ala' M Abuh-Odeh, Wamidh H Talib","doi":"10.1177/15347354251413219","DOIUrl":"10.1177/15347354251413219","url":null,"abstract":"<p><p><i>Prangos ferulacea</i> is a widely recognized and valuable medicinal herb known for its diverse biological characteristics. Our study was conducted to evaluate the anticancer and immunomodulatory effects of <i>P. ferulacea</i>. Ethyl acetate, methanol, and aqueous extracts were prepared from <i>P. ferulacea</i>, and the MTT assay was used to measure antiproliferation activity against 5 cancer cell lines (MDA-MB231, T47-D, HeLa, EMT6/P, and Vero). The 3 extracts underwent a qualitative LC/MS spectrometry analysis to determine each extract's composition. The MTT test was used to measure the proliferation of lymphocytes. Extracts were evaluated for their effects on macrophages phagocytic activity and pinocytosis function using the nitro blue tetrazolium assay and the neutral red method, respectively. The impact of ethyl acetate and methanol was assessed in mice inoculated with EMT6/P using the in vivo model, and the tumor size was measured. Results showed that ethyl acetate and methanol extracts had the highest activity against T47-D with IC₅₀ values of 0.019 mg/ml. The ethyl acetate extract exhibited moderate effectiveness against the following cell lines: MDA-MB-231 and EMT6/P with IC₅₀ values of 0.104 and 0.255 mg/ml, respectively. Meanwhile, methanol extract showed activity against MDA-MB231 and EMT6/P cell lines and had IC₅₀ values of 0.214 and 0.31 mg/ml, respectively. Regarding immunomodulatory assays, the methanol extract, followed by the ethyl acetate extract, significantly increases lymphocyte proliferation and macrophage phagocytosis activity. Aqueous extracts increase the activity of pinocytosis. Both ethyl acetate and methanol extracts reduced tumor size by 61.46% and 34.47%, respectively. They also decreased the average weight of the tumor cells in the in vivo model. The results of <i>P. ferulacea</i> have valuable activity against cancer cells and stimulate the immune system. However, further molecular investigations are required to understand the mechanism of action of <i>P. ferulacea</i> activity.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354251413219"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12979902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147432678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Letter to the Editor: Comment on \"The Efficacy and Safety of Nutritional Supplements for Cancer Supportive Care: An Umbrella Review and Hierarchical Evidence Synthesis\".","authors":"Sarah Benna-Doyle, Suzanne Jane Grant, Carolyn Ee","doi":"10.1177/15347354261443237","DOIUrl":"10.1177/15347354261443237","url":null,"abstract":"","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261443237"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13080187/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147673058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Moxibustion Promotes Tumor Immune Responses and Vascular Normalization to Enhance Antitumor Effect of Cisplatin in Lewis Lung Carcinoma Mice.","authors":"Shanshan Lu, Jiaqi Wang, Yue Pan, Yuanzhen Yang, Jin Huang, Shanshan Li, Bin Wang, Suhong Zhao, Ning Ma, Jiayue Zhao, Jing Huang, Yi Guo, Zhifang Xu","doi":"10.1177/15347354261450974","DOIUrl":"10.1177/15347354261450974","url":null,"abstract":"<p><p>The immunosuppressive tumor microenvironment and vascular abnormalities are important factors affecting the anticancer effects of chemotherapeutic drugs. Previous studies have shown that moxibustion combined with cisplatin can improve tumor immunity and vascular normalization. The aim is to further explore the pathways and molecular mechanisms by which moxibustion combined with cisplatin exerts anti-tumor effects through regulating the tumor immune-vascular microenvironment. Through RNA sequencing and bioinformatics analysis, we identified related signaling pathways and key molecules, which were subsequently validated at both cellular and molecular levels. The combination of moxibustion and cisplatin enhanced the infiltration of CD4⁺ T cells and myeloid dendritic cells in tumor tissues. Moreover, it elevated the M1/M2 and Th1/Th2 ratios along with enhanced Th1 cell polarization. This therapeutic approach modulated immune-related molecules through upregulation of Il2 and downregulation of Il1β at the mRNA level, accompanied by decreased protein expression of CXCL1, IL-13, CCL3, and CCL4. Furthermore, moxibustion upregulated <i>Ifnγ</i> and <i>Pf4</i> mRNA levels and downregulated <i>Vegfa</i> and <i>Flt1</i>. Thus, the imbalance between pro-angiogenic and anti-angiogenic factors in the tumor microenvironment can be corrected. Notably, the anti-tumor effects of moxibustion combined with cisplatin were abrogated upon intratumoral injection of the IFN-γ neutralizing antibody, suggesting the critical role of IFN-γ. The findings demonstrate that the combination of moxibustion and cisplatin can enhance tumor immunity, inhibit tumor angiogenesis. This therapeutic effect is potentially mediated through the upregulation of IFN-γ.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261450974"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13498794/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147972231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GO-Y078 Triggers Program Cell Death in Human Cervical Cancer Cells Via MAPK Activation-Dependent Apoptotic Caspases Signaling.","authors":"Chung-Yuan Lee, Po-Hui Wang, Yi-Hsien Hsieh, Yi-Hsuan Hsiao, Chih-Hsin Tang, Tzu-Yu Huang, Shun-Fa Yang, Pei-Ni Chen","doi":"10.1177/15347354251411859","DOIUrl":"10.1177/15347354251411859","url":null,"abstract":"<p><p>Apoptosis is a regulated process of programed cell death that removes damaged ells. GO-Y078, a new curcumin analog, has been studied in the oncology field and shown to exert anti-proliferative and anti-angiogenic effects in multiple tumor types. However, its detailed signaling mechanisms and functional effects in human cervical cancer have not been clarified. Herein, GO-Y078 was employed to examine the anti-cancer mechanism in cervical cancer cells. GO-Y078 reduced the cell viability and elicited chromatin condensation and apoptotic cells of human cervical SiHa and HeLa cancer cells. Active PARP and active caspase-9, -8, and -3 were involved in GO-Y078-stimulated apoptosis. GO-Y078 also elevated phosphorylation of mitogen-activated protein kinase (MAPK) pathway. Co-treatment with GO-Y078 and either the ERK inhibitor U0126 or the p38 inhibitor SB203580 significantly reduced GO-Y078-induced activation of caspase-9, -8, and -3. In conclusion, GO-Y078 is a potential therapeutic candidate that induces apoptotic cell death in cervical cancer cells through phosphorylation-dependent activation of MAPK signaling followed by caspase activation.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354251411859"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13153533/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147770703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of <i>Viscum album L.</i> in Patients With Triple-Negative Breast Cancer Receiving Immune Checkpoint Inhibitors: A Protocol for an Open-Label Randomized Clinical Trial.","authors":"Jee Young Lee, Eun Ju Ko, Sang Hyung Lee, Sung Eun Hong, Myung Han Hyun","doi":"10.1177/15347354261483616","DOIUrl":"10.1177/15347354261483616","url":null,"abstract":"<p><p>Although pembrolizumab has shown clinical benefit in triple-negative breast cancer (TNBC), effective long-term responses remain limited. <i>Viscum album</i> (mistletoe extracts, VA) may have immunomodulatory, pro-apoptotic, and immune-stimulating effects in preclinical and clinical studies. This trial was designed to evaluate the immunologic effects and safety of combining pembrolizumab with VA in the adjuvant setting. This open-label, randomized, clinical trial will include 40 adults (≥19 years) with histologically confirmed TNBC who have undergone surgery and started adjuvant pembrolizumab but received adjuvant pembrolizumab no more than three cycles. Participants will be randomized 1:1 to receive pembrolizumab plus <i>Viscum album</i> (VA group, n = 20) or to the wait-list group (n = 20). VA will be administered subcutaneously in escalating doses for 18 weeks. The primary endpoint will be the change in immune-related markers (e.g., interferon gamma, tumor necrosis factor-alpha, interleukin [IL]-2, IL-12, IL-15) assessed at baseline and weeks 4, 7, and 19. Secondary endpoints will include quality of life and safety. This ongoing study will explore whether the addition of VA enhances systemic immune activation, as reflected by cytokine modulation, and improves patient-reported quality of life without increasing adverse events. The integration of VA with pembrolizumab may offer synergistic benefits by augmenting immune responses within the tumor microenvironment. This trial is expected to generate clinical evidence regarding the immunologic implications, safety, and feasibility of this combined regimen, informing future strategies for adjuvant treatment of TNBC. The trial has been registered at https://ClinicalTrials.gov (registration identifier: NCT06920810).</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261483616"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13525282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148828125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fuzheng Buxue Dietary Therapy-Preconditioned MSC-Derived Extracellular Vesicles Promote Hematopoietic Recovery in Chemotherapy-Induced Myelosuppression.","authors":"Mingwan Yin, Huize Dong, Wenjing Tu, Shuxia Yan, Ran Ye, Guihua Xu, Min Yang","doi":"10.1177/15347354261482129","DOIUrl":"10.1177/15347354261482129","url":null,"abstract":"<p><p>BackgroundChemotherapy-induced myelosuppression (CIM) is a common dose-limiting toxicity that compromises chemotherapy continuity and patient outcomes. In the bone marrow microenvironment, mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) act as key paracrine mediators, regulating the function of CD34+ hematopoietic stem and progenitor cells (HSPCs). Based on the traditional concept of medicine-food homology, our team has developed Fuzheng Buxue dietary therapy (FBDT) and previously demonstrated its clinical efficacy in alleviating CIM. This study investigates whether FBDT alleviates CIM by modulating MSC-EV function.MethodsIn vitro, the optimal conditions for 5-fluorouracil (5-FU)-induced injury and FBDT intervention were first determined. CD34+ HSPCs were co-cultured with FBDT-preconditioned MSCs (FBDT-MSCs), and the expression of surface markers CD117 and CD150 was evaluated. Subsequently, EVs were isolated from FBDT-MSCs and co-cultured with CD34+ HSPCs. HSPC viability and CD117/CD150 expression were assessed. In vivo, a 5-FU-induced CIM rat model received tail vein injections of EVs from FBDT-MSCs (FBDT-EVs). Body weight, peripheral blood parameters, and serum CD117 and SCF levels were measured. Histopathology and organ indices of spleen, thymus, and bone marrow were analyzed. Key hematopoietic regulators (CD117, SCF, CD90) in bone marrow were detected by Western blot. Finally, serum creatinine levels in rats were measured.ResultsCo-culture with FBDT-MSCs increased HSPC numbers but did not significantly alter the distribution of CD117/CD150-defined HSPC subpopulations. FBDT-EVs enhanced the viability of CD34+ HSPCs in the co-culture system and increased the proportion of CD117+CD150+ HSPCs. Furthermore, FBDT-EVs promoted the recovery of hematopoietic function in CIM rats, with the reversal of body weight loss and restoration of key blood cell parameters. FBDT-EVs reduced CD117 protein levels in both bone marrow tissue and serum, while upregulating the expression of SCF and CD90. Serum creatinine levels were not significantly altered, suggesting no apparent renal toxicity under the present experimental conditions.ConclusionThe study identifies MSC-EVs as a potential mediator of the hematopoietic effects of FBDT and suggests that FBDT may enhance the hematopoietic reparative properties of MSC-EVs. These findings suggest that MSC-EVs may mediate, at least in part, the hematopoietic effects of FBDT and that FBDT preconditioning enhances the hematopoietic reparative potential of MSC-EVs in CIM.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261482129"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13519230/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148818225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Phase I Randomized, Placebo-Controlled, Cross-Over Dose-Finding Study of Coenzyme Q₁₀ on Doxorubicin Pharmacokinetics During Breast Cancer Treatment\".","authors":"Zhihao Lei","doi":"10.1177/15347354251414639","DOIUrl":"10.1177/15347354251414639","url":null,"abstract":"","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354251414639"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12811552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145989158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Sodium Ascorbate High Dose on Quality of Life and Pain in Patients Diagnosed With and Treated for Terminal Cancer (Real-World Data Study).","authors":"Hugo Mario Galindo Salom, Carlos Alberto Carrillo Bravo, Helber Armando Prieto Lozano, Paulo Andrés López Posada","doi":"10.1177/15347354251414640","DOIUrl":"10.1177/15347354251414640","url":null,"abstract":"<p><p>Cancer pain is a complex issue of significant importance in daily clinical practice, requiring a multidimensional approach. Approximately 90% of cancer pain cases can be effectively managed through the appropriate and often combined use of pharmacological and non-pharmacological treatments. In addition to the analgesic drugs outlined in the WHO analgesic ladder, the concurrent use of adjuvant drugs may be considered, which are sometimes essential for effective cancer pain management. These treatments can be adjusted based on the presence of inflammatory processes and oxidative stress.</p><p><strong>Methodology: </strong>This is an observational, descriptive, retrospective, real-world data study conducted in daily practice at the Country Medical Center in Bogotá, Colombia. It involved patients with any type of cancer diagnosis who were receiving chemotherapy, radiotherapy, oncological surgery, and/or hormonal therapy. From 2018 to 2023, protocols for intravenous high dose of sodium ascorbate were applied, resulting in a sample of 92 patients.</p><p><strong>Results: </strong>The administration of sodium ascorbate at dose of 100 to 300 and 300 to 600 mg/kg/day showed statistically significant improvements in quality of life (<i>P</i> = .000). However, only the 300 to 600 mg/kg/day dose demonstrated a statistically significant reduction in pain (<i>P</i> = .0061).</p><p><strong>Conclusions: </strong>It is possible that by controlling or reducing inflammation, pain sensation can be decreased, therefore high dose of an antioxidant such as sodium ascorbate may be an alternative to improve oxidative stress and inflammation as an adjuvant to analgesic prescription according to pain management guidelines for cancer patients.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354251414640"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12855741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146085616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lack of Successful Implementation of Cancer Rehabilitation Guidelines: A Mixed-methods Study Highlighting Need for Better Preconditions in Primary Care.","authors":"Maria Lindberg, Anna Efverman","doi":"10.1177/15347354261420179","DOIUrl":"10.1177/15347354261420179","url":null,"abstract":"<p><p>Implementing cancer rehabilitation in primary care that addresses the physical, psychological, social, and existential consequences of cancer is considered important.</p><p><strong>Aim: </strong>To describe primary care practitioners' self-reported preconditions-including facilitators and barriers-related to cancer rehabilitation and physical activity, as well as their interest in responding to questions about cancer rehabilitation.</p><p><strong>Methods: </strong>This convergent mixed-methods study collected self-reported quantitative questionnaire data using 0 to 10 scales (10 = maximum) from 229 primary care practitioners (104 rehabilitation practitioners and 125 healthcare center practitioners), and written qualitative data from a sub-sample of 120.</p><p><strong>Results: </strong>Among rehabilitation practitioners, 20% provided some form of cancer rehabilitation and 70% prescribed physical activity to consulting cancer survivors. Corresponding figures for healthcare center practitioners were 10% and 15%, respectively. Both rehabilitation and healthcare center practitioners reported a median score of 0 (no knowledge) regarding physical activity advice for cancer survivors, and 95% of participants had not read cancer rehabilitation guidelines. Rehabilitation practitioners gave median ratings of 8 and 9 for the importance of providing cancer rehabilitation and physical activity advice, respectively, compared with 6 and 7 among healthcare center practitioners. Median ratings among rehabilitation practitioners were 3 for workplace preparedness and 3 for sufficient time for cancer rehabilitation, compared with 2 and 0 (no time at all) among healthcare center practitioners. Facilitators of the implementation were that providing cancer rehabilitation was considered important, and that practitioners were experienced in rehabilitation and physical activity counseling in non-cancer populations. To have committed and motivated co-workers facilitated a positive work culture for cancer rehabilitation. Primary barriers were the limited knowledge and skills and perceived unsatisfactory organizational preconditions, shaping an uncertainty on if primary care has any responsibility for cancer rehabilitation. Of the 168 rehabilitation practitioners invited, 104 (62%) were interested in answering questions regarding cancer rehabilitation. Among the 1055 invited healthcare center practitioners, 125 (12%) were interested.</p><p><strong>Conclusions: </strong>Given the limited preconditions for cancer rehabilitation and physical activity implementation, the described barriers and facilitators, and the varying interest among practitioners, educational interventions and support strategies tailored to both individuals and organizations appear necessary.</p>","PeriodicalId":13734,"journal":{"name":"Integrative Cancer Therapies","volume":"25 ","pages":"15347354261420179"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12929825/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147270985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}